PRTA
Prothena Corporation plc
32.25
USD
This page is just a preview of the data found in TrendSpider’s full version
Prothena Corporation plc stock is down -9.08% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 10 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 27 Nov 20:45 | 19 Jan, 2024 | 25.00 | 5063 | ||
| 27 Nov 20:45 | 19 Jan, 2024 | 25.00 | 5063 | ||
| 27 Nov 20:45 | 19 Jan, 2024 | 25.00 | 5063 | ||
| 27 Nov 20:46 | 19 Jan, 2024 | 25.00 | 5063 | ||
| 27 Nov 20:46 | 19 Jan, 2024 | 35.00 | 572 | ||
| 27 Nov 20:47 | 19 Jan, 2024 | 25.00 | 5063 | ||
| 28 Nov 15:05 | 15 Dec, 2023 | 35.00 | 2926 | ||
| 28 Nov 15:43 | 15 Dec, 2023 | 35.00 | 2926 | ||
| 28 Nov 15:43 | 15 Dec, 2023 | 35.00 | 2926 | ||
| 28 Nov 16:08 | 15 Dec, 2023 | 35.00 | 2926 |
Prothena Corporation plc focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, is in clinical trials for Parkinson's disease; PRX004, which completed Phase I clinical trial.
